论文部分内容阅读
太安堂(002433)目前产品领域覆盖皮肤病用药、心脑血管用药与不孕不育等。公司于2010年登陆资本市场,此后,通过一系列收购兼并,产品种类从上市之初的108个大幅增加到350多个,其中有二十多个是独家产品,不乏心宝丸、麒麟丸等重磅产品。目前,公司通过内外部资源整合,致力于打造现代中药强企的目标正在步步实现,而公布的2012年年报数据显示,公司快速成长的苗头已初步显现,投资价值有待进一步挖掘。
Tai On Hall (002433) The current product areas covered dermatology medication, cardiovascular medicine and infertility. The company landed on the capital market in 2010, and since then, through a series of mergers and acquisitions, the product range has risen sharply from 108 at the beginning of the listing to more than 350, of which over 20 are exclusive products, including Xinbao Pills and Kirin Pills Heavy products. At present, the Company’s goal of building a strong enterprise with modern Chinese medicine through the integration of internal and external resources is being realized step by step. According to the published data of the 2012 annual report, the rapid growth of the Company has shown its initial appearance and its investment value needs to be further tapped.